Skip to main content

Advertisement

SpringerLink
Log in

Durchfälle und Bauchschmerzen – was steckt dahinter?

Chronisch entzündliche Darmerkrankungen

  • FORTBILDUNG_ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Morbus Crohn und Colitis ulcerosa sind ernstzunehmende chronische Erkrankungen, deren Pathogenese letztlich noch immer nicht verstanden ist. Bringen Sie sich auf den neuesten Stand und erfahren Sie mehr über die aktuellen therapeutischen Möglichkeiten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2013;9(6):367–74

    Google Scholar 

  2. Wu GD, Lewis JD. Analysis of the Human Gut Microbiom and Association With Disease. Clin Gastroenterol Hepatol 2013:11;774–777

    Article  PubMed  Google Scholar 

  3. Magin WS, van Kruiningen HJ, Colombel JF et al. Immunohistochemichal Search for Viral and Bacterial Antigens in Crohns Disease. J Crohns Colitis 2013;7:161–166

    Article  PubMed  Google Scholar 

  4. Brant SR. Promises, Delivery and Challenges of Inflammatory Bowel Disease Risk Gene Discovery. Clin Gastroenterol Hepatol 2013; 11:22–26

    Article  PubMed  Google Scholar 

  5. Jostins L, Ripke S, Weersma RK et al. Host-Microbe Interactions Have Shaped the Genetic Architecture of Inflammatory Bowel Disease. Nature 2012;491:119–124

    Article  PubMed  CAS  Google Scholar 

  6. Wehkamp J, Stange EF. Paneth’s Disease. J Crohns Colitis 2010;4:523–531

    Article  PubMed  Google Scholar 

  7. Bonaz BL, Bernstein ChN. Brain-Gut Interactions in Inflammatory Bowel Disease. Gastroenterology 2013;144:36–49

    Article  PubMed  Google Scholar 

  8. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus and Implications. Gut 2006;55:749–753

    Article  PubMed  CAS  Google Scholar 

  9. Langholz E. Current Trends in Inflammatory Bowel Disease: The Natural History Therap Adv Gastroenterol 2010;3:77–86

    Google Scholar 

  10. Danese S, Fiocchi C. Ulcerative Colitis. NEJM 2011;365:1713–1725

    Article  PubMed  CAS  Google Scholar 

  11. Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431–440

    Article  PubMed  Google Scholar 

  12. Burisch J, Jess T, Martinato M, Lakatos PL. The Burden of Inflammatory Bowel Disease in Europe. J Crohns Colitis 2013;7:322–337

    Article  PubMed  Google Scholar 

  13. Jess T, Simonsen J, Jørgensen KT et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30years. Gastroenterology 2012;143:375–381

    Article  PubMed  Google Scholar 

  14. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10(6):639–645

    Article  PubMed  Google Scholar 

  15. Beaugerie L, Svrcek M, Seksik P et al. Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. Gastroenterology 2013;145:166–175

    Article  PubMed  Google Scholar 

  16. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11:43–48

    Article  PubMed  Google Scholar 

  17. Dignass A, Eliakim R, Magro F et al. Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis. J Crohns Colitis 2012;6:965–990

    Article  PubMed  Google Scholar 

  18. Dignass A, Preiß JC, Aust DE et.al. Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011–Ergebnisse einer Evidenzbasierten Konsensuskonferenz Z Gastroenterol 2011;49;1276–1341

    CAS  Google Scholar 

  19. Panes J, Bouhnik Y, Reinisch W et al. Imaging Techniques for Assessment of Inflammatory Bowel Disease: Joint ECCO and ESGAR Evidence- Based Consensus Guidelines. J Crohns Colitis 2013;7:556–585

    Article  PubMed  CAS  Google Scholar 

  20. Dignass A, Van Assche G, Lindsay JO et al. The Second European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease: Current Management. J Crohns Colitis 2010;4:28–62

    Article  PubMed  CAS  Google Scholar 

  21. Van Assche G, Dignass A, Reinisch W et al. The Second European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease: Special Situations. J Crohns Colitis 2010;4:63–101

    Article  PubMed  Google Scholar 

  22. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2):47–91

    Article  PubMed  CAS  Google Scholar 

  23. Teich N, Klugmann T, Tiedemann A et al. Impfschutz bei Immunsupprimierten: Ergebnisse eines regionalen Versorgngsprojekts. Dtsch Ärztebl 2011;108(7):105–111

    Google Scholar 

  24. Prantera C, Lochs H, Grimaldi M et al. Rifaximin- extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology 2012; 142(3):473–481

    Article  PubMed  CAS  Google Scholar 

  25. Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn’s disease. Worl J Gastroenterol 2013;19(5):648–653

    Article  Google Scholar 

  26. Khan KJ, Ullman TA, Ford AC. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661–673

    Article  PubMed  CAS  Google Scholar 

  27. Khan N, Abbas AM, Lichtenstein GR et al. Risk of Lymphoma in Patients with Ulcerative Colitis Treated with Thiopurines–a Nationwide Retrospective Cohort Study. Gastroenterology doi:10.1053/j.gastro. 2013.07.035

    Google Scholar 

  28. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2011;106:644–659

    Article  PubMed  CAS  Google Scholar 

  29. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2012;142:257–265

    Article  PubMed  CAS  Google Scholar 

  30. Reinisch W, Sandborn WJ, Rutgeerts P et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201–211

    Article  PubMed  Google Scholar 

  31. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005;128:862–869

    Article  PubMed  CAS  Google Scholar 

  32. Lee JC. Predicting the Course of IBD: Light at the End of the Tunnel? Dig Dis 2012;30 (Suppl1):95–99

    Article  PubMed  Google Scholar 

  33. Reinisch W, Panes J, Lemann M et al. A multicenter, randomized, double blind trial of everolimus vs azathioprine and placebo to maitain steroid induced remission in patients with moderate to severe Crohn’s disease. Am J Gastroenterol 2008;103:2284–2292

    Article  PubMed  CAS  Google Scholar 

  34. Yamamoto S, Nakase H, Mikami S et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:598–97

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Marienkrankenhaus, Frankfurt/Main, Deutschland

    Franz Hartmann

Authors
  1. Franz Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franz Hartmann.

Additional information

This article is part of a supplement not sponsored by the industry.

Interessenskonflikt

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ. Er legt folgende potenzielle Interessenkonflikte offen: Vortrags- und Beratungstätigkeit für AbbVie, MSD, Falk und Vifor.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartmann, F. Durchfälle und Bauchschmerzen – was steckt dahinter?. MMW - Fortschritte der Medizin 155, 57–63 (2013). https://doi.org/10.1007/s15006-013-2128-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-013-2128-x

Keywords - Inflammatory Bowel Diseases

Search

Navigation